📄 medicine

Association Between a Novel MTV-Based Effective Absorbed Dose Index and ALBI Score Changes in Metastatic Colorectal Cancer Patients Treated with Yttrium-90 Glass Microspheres

This study demonstrates that a novel MTV-based Effective Absorbed Dose Index, derived from the ratio of tumour to non-tumoural liver absorbed doses, is significantly associated with stable liver function (ALBI score) in metastatic colorectal cancer patients treated with Yttrium-90 glass microspheres, suggesting its potential utility for optimizing individualized treatment planning and risk stratification.

Original authors: Efe Soydemir, Şerife Çetin, Özlem Erez, Selin Kesim, Erbil Arık, Zeynep Ceren Balaban Genç, Ecem Ceran, Nihat Zümbül, Alper Eroğlu, Tanju Yusuf Erdil, Nuri Çagatay Çimşit, Tunç Öneş

Published 2026-06-28

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Efe Soydemir, Şerife Çetin, Özlem Erez, Selin Kesim, Erbil Arık, Zeynep Ceren Balaban Genç, Ecem Ceran, Nihat Zümbül, Alper Eroğlu, Tanju Yusuf Erdil, Nuri Çagatay Çimşit, Tunç Öneş

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: A High-Stakes Balancing Act

Imagine the liver as a busy city. In patients with metastatic colorectal cancer, the "criminals" (cancer cells) have set up illegal bases all over this city. The doctors want to send in a specialized cleanup crew (radiation) to destroy these bases without burning down the whole city.

The treatment used here is called TARE (Transarterial Radioembolization). It's like firing tiny, radioactive "bullets" (Yttrium-90 glass microspheres) directly into the liver's blood supply. These bullets seek out the cancer and explode, killing the tumor cells.

The Problem: It's hard to aim perfectly. If you fire too many bullets, you might destroy the cancer, but you also risk damaging the healthy parts of the city (the normal liver tissue). If the healthy liver gets too hurt, the patient's liver function fails.

The New Tool: A "Scorecard" for Safety

The researchers wanted to find a better way to predict if a patient's liver would survive the treatment. They created a new mathematical formula called the MTV-based Effective Absorbed Dose Index.

To understand this, imagine two buckets:

Bucket A (The Bad Guys): This bucket holds the total radiation dose hitting the cancer.
Bucket B (The Good Guys): This bucket holds the total radiation dose hitting the healthy liver.

Usually, doctors just look at how much radiation is in Bucket A. But this study says, "That's not enough! We need to know the ratio."

They also measured the MTV (Metabolic Tumor Volume), which is like measuring the actual size of the criminal gang's territory on a map.

The new "Scorecard" works like this:

It takes the radiation hitting the cancer and divides it by the size of the cancer (How much power per criminal?).
It takes the radiation hitting the healthy liver and divides it by the size of the healthy liver (How much power per innocent citizen?).
Finally, it compares these two numbers.

The Analogy: Think of it like a school exam.

If the "cancer score" is high (lots of radiation hitting the tumor) and the "healthy liver score" is low (very little radiation hitting the good parts), the Index Score is High.
The study found that a High Index Score is a good thing. It means the treatment is hitting the bad guys hard while sparing the good guys.

What They Found

The team looked at 77 patients who had 93 of these treatments. They checked the patients' liver health before and after using a standard test called the ALBI score (which is like a report card for how well the liver is working).

The Result: In about 20% of the treatments, the liver's "report card" got worse (the ALBI score dropped).
The Connection: They found that when the new Index Score was high, the liver's report card usually stayed stable. When the Index Score was low, the liver was more likely to get hurt.
The Prediction: The new score was pretty good at predicting who would stay safe. If the score was high, there was an 88% chance the liver function would not get worse.

The "Cut-Off" Lines

The researchers tried to find a specific number on their scorecard that acts as a warning light.

The "65" Line: If the score is below 65, it's a warning sign that the liver might get hurt soon (like a yellow traffic light).
The "156" Line: If the score is above 156, it's a green light, suggesting the treatment is very safe for the liver, even if the patient has had many treatments before.

They noticed something interesting: One patient had a score between 65 and 156 (the "grey zone"). Even though the doctors lowered the radiation dose for that patient, the liver still got hurt. This suggests that while the score is helpful, it's not a magic crystal ball, and doctors still need to be careful.

The Bottom Line

This study introduces a new way of doing the math before and after radiation treatment. Instead of just counting how much radiation was used, this new method looks at how efficiently that radiation was used to hit the cancer versus the healthy liver.

If the new "Index Score" is high, it suggests the treatment plan was a good balance: it attacked the cancer effectively while protecting the liver. This helps doctors decide if it's safe to give a patient another round of treatment later on.

Important Note: The paper states this is based on a specific group of patients at one hospital. While the results are promising, the authors say we need more studies to confirm this works for everyone before it becomes a standard rule for all doctors.

Technical Summary: Association Between a Novel MTV-Based Effective Absorbed Dose Index and ALBI Score Changes in Metastatic Colorectal Cancer Patients Treated with Yttrium-90 Glass Microspheres

Problem Statement
Transarterial radioembolization (TARE) with Yttrium-90 ( $^{90}$ Y) glass microspheres is a established locoregional therapy for metastatic colorectal cancer (mCRC) with liver-dominant disease. While the therapeutic goal is to deliver high-dose radiation to tumor tissue while sparing non-tumoral liver parenchyma, the relationship between dosimetric parameters and post-treatment liver function remains insufficiently characterized, particularly in patients undergoing repeated TARE sessions. Although metabolic imaging parameters like Metabolic Tumor Volume (MTV) are used for response assessment, their integration with dosimetric data and liver function biomarkers is limited. Furthermore, while the Albumin-Bilirubin (ALBI) score is a recognized objective biomarker for hepatic functional reserve, its correlation with personalized dosimetry in mCRC patients treated with $^{90}$ Y glass microspheres has not been fully explored.

Methodology
This study analyzed a cohort of 77 mCRC patients who underwent a total of 93 TARE procedures with $^{90}$ Y glass microspheres between September 2017 and June 2023. The study design included both retrospective and prospective data collection.

Imaging and Dosimetry: Pre-treatment planning utilized $^{99m}$ Tc-MAA SPECT/CT. Post-treatment dosimetry was performed using $^{90}$ Y Bremsstrahlung SPECT/CT images coregistered with diagnostic CT, MRI, or $^{18}$ F-FDG PET/CT using Simplicit90Y™ software.
Volume Segmentation: Volumes of interest (VOIs) were segmented to define perfused tumor, normal liver tissue, and viable tumor regions.
Novel Index Calculation: The study introduced a "MTV-based Effective Absorbed Dose Index." This was derived by normalizing absorbed doses to tissue volumes:
- Index A (Tumor Dose Index): $(\text{Perfused tumor absorbed dose} / \text{MTV}) \times 100$
- Index B (Normal Liver Dose Index): $(\text{Non-tumoral liver absorbed dose} / \text{Normal liver volume}) \times 100$
- Effective Absorbed Dose Index: Calculated as the ratio $A/B$ .
Liver Function Assessment: The ALBI score was calculated at baseline and at 8–9 weeks post-TARE using serum albumin and bilirubin levels. Changes in ALBI score were categorized to assess liver function preservation or deterioration.
Statistical Analysis: The association between the MTV-based Effective Absorbed Dose Index and ALBI score changes was evaluated using the Mann-Whitney U test. Receiver Operating Characteristic (ROC) curve analysis was performed to determine the predictive performance of the index for ALBI score deterioration.

Key Results

Cohort Characteristics: The median age was 65 years. The median absorbed dose to perfused tumor tissue was 137.6 Gy, while the median dose to healthy liver parenchyma was 19.6 Gy. The median MTV reduction was 29.4%.
Association with Liver Function: ALBI score deterioration occurred in 20.4% of the TARE sessions (19 out of 93). Higher MTV-based Effective Absorbed Dose Index values were significantly associated with the preservation of liver function (stable ALBI scores) ( $p = 0.038$ ). The index demonstrated a negative predictive value of 88% for ALBI deterioration.
Predictive Performance: ROC analysis indicated moderate predictive ability for the index in forecasting ALBI score deterioration, with an Area Under the Curve (AUC) of 0.66 ( $p = 0.038$ ).
Cut-off Values: Two potential cut-off values were identified using the Youden index method:
- Cut-off 65: Provided higher specificity (79.7%) and was considered more clinically useful for identifying patients at risk of ALBI deterioration.
- Cut-off 156: Provided higher sensitivity (73.7%) and was noted to correctly identify patients who developed Radioembolization-Induced Chronic Hepatotoxicity (RECHT), even when ALBI scores remained stable.
Toxicity and Survival: The toxicity profile was generally favorable. Among the 19 cases of ALBI deterioration, specific cases of Radioembolization-Induced Liver Disease (REILD) and RECHT were analyzed in relation to the index values. Survival data showed a median overall survival of 13.6 months after the first TARE procedure.

Significance and Claims
The authors claim that the MTV-based Effective Absorbed Dose Index represents a novel metric that integrates personalized dosimetry with metabolic tumor burden and functional liver assessment. The study posits that this index provides a clinically useful tool for balancing therapeutic efficacy and hepatic toxicity in TARE.

Specifically, the paper claims:

Risk Stratification: The index can support individualized treatment planning and risk stratification for patients with liver-dominant mCRC.
Complementary Cut-offs: The study suggests that two distinct cut-off values may serve complementary roles: a lower cut-off (65) for detecting patients at risk of progressive ALBI deterioration and REILD, and a higher cut-off (156) for identifying risks of RECHT even in the absence of immediate ALBI score changes.
Clinical Utility: By accounting for the relative distribution of radiation between tumor burden and non-tumoral liver parenchyma, the index offers a more comprehensive framework than absolute tumor dose metrics alone.

The authors conclude that while the findings are promising, they are based on a single-center cohort with partly retrospective data. They state that prospective multicenter validation is warranted to confirm the utility of this index in pre-treatment planning to guide dose adjustments and improve safety in repeat TARE sessions.